Today: 30 June 2026
Opendoor stock rises in premarket as OPEN nears $6.24 incentive level after CFO change
2 January 2026
1 min read

Opendoor stock rises in premarket as OPEN nears $6.24 incentive level after CFO change

NEW YORK, Jan 2, 2026, 07:40 ET — Premarket

  • Opendoor shares rose about 2% in premarket trading, after a Dec. 31 close at $5.83
  • A recent SEC filing detailed a new CFO effective Jan. 1 and stock awards tied to a $6.24 average-price hurdle
  • Traders are watching U.S. data on jobs and construction spending for clues on rates and housing demand

Opendoor Technologies Inc (OPEN) shares were up 2.1% at $5.95 in premarket trading on Friday. The stock closed at $5.83 on Dec. 31 after trading between $5.77 and $6.00, according to Investing.com data.

The real-estate platform is an “iBuyer” — it uses its own balance sheet to buy homes directly, then resells them — leaving results highly exposed to funding costs and home-price swings.

That matters early in the year because shifts in interest-rate expectations can quickly change mortgage affordability and transaction volumes, which tend to ripple into rate-sensitive housing names.

A Dec. 15 regulatory filing showed Opendoor named Christy Schwartz as chief financial officer effective Jan. 1, and hired Lucas Matheson, formerly head of Coinbase Canada, as president. The filing also disclosed performance-based stock awards for both executives that begin vesting if OPEN averages at least $6.24 over 30 trading days, with higher hurdles set at $9 to $33.

“We looked everywhere,” CEO Kaz Nejatian said in the accompanying press release, adding the best CFO candidate “was already here.” The company said Matheson will oversee strategic initiatives, including exploring blockchain technology and “tokenization.” SEC

Tokenization is a broad term for creating digital tokens that represent an ownership claim in an asset. Performance restricted stock units (PRSUs), meanwhile, are stock awards that vest only if specific share-price targets are met and the executive remains employed.

At around $5.95, OPEN was roughly 5% below the $6.24 threshold disclosed in the filing, a level some traders may treat as a near-term marker given the performance conditions attached to executive pay.

On the macro calendar, investors will get weekly initial jobless claims at 8:30 a.m. and November construction spending at 10:00 a.m. The ISM manufacturing survey is due on Monday, according to the New York Fed’s economic indicators calendar.

Those releases can jolt Treasury yields, which feed into mortgage rates and refinancing activity — a key variable for housing demand and for companies that finance home inventory.

The next major company catalyst is quarterly results expected in late February; Investing.com lists Feb. 26 as the next earnings date.

Investors typically focus on how many homes Opendoor is buying and selling, how quickly it is turning inventory, and what it is paying to finance those homes. Any read-through on cash burn and pricing discipline tends to matter as much as headline revenue.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
Chevron stock today: CVX steadies near $152 as oil logs steepest annual drop since 2020
Previous Story

Chevron stock today: CVX steadies near $152 as oil logs steepest annual drop since 2020

Hyperscale Data (GPUS) stock jumps 20% in premarket as insider buying keeps spotlight on the microcap
Next Story

Hyperscale Data (GPUS) stock jumps 20% in premarket as insider buying keeps spotlight on the microcap

Go toTop